SCHEMBL4130592

SCHEMBL4130592

Cn1[nH]c(=O)c2cc(-c3nc4cc(C(=O)NS(=O)(=O)c5ccccc5)ccc4n3C3CCCCC3)ccc2c1=O

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 11/20 0.48
L3MBTL1 Q9Y468 1/20 0.44
BCAT2 O15382 1/20 0.40
BRD4 O60885 1/20 0.40
CYP3A4 P08684 1/20 0.39
EPHX2 P34913 1/20 0.39
PPARG P37231 1/20 0.39
CYSLTR1 Q9Y271 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125742 0.86 L3MBTL1 (0.58) PTGER4L3MBTL1
SCHEMBL4129831 0.84 PTGER4 (0.47) PTGER4L3MBTL1BCAT2CYP3A4HDAC1
SCHEMBL4117074 0.83 PTGER4 (0.46) PTGER4L3MBTL1BCAT2CYP3A4HDAC1
SCHEMBL13905079 0.81 PTGER4 (0.46) PTGER4L3MBTL1BCAT2CYP3A4HDAC1
SCHEMBL4125831 0.81 L3MBTL1 (0.47) PTGER4L3MBTL1BCAT2CYP3A4CYSLTR1
SCHEMBL13905099 0.80 L3MBTL1 (0.46) PTGER4L3MBTL1BCAT2CYP3A4CYSLTR1
SCHEMBL4117565 0.79 L3MBTL1 (0.45) PTGER4L3MBTL1BCAT2BRD4CYP3A4
SCHEMBL4129720 0.79 L3MBTL1 (0.45) PTGER4L3MBTL1BCAT2CYP3A4HDAC1
SCHEMBL4117061 0.78 L3MBTL1 (0.43) PTGER4L3MBTL1BCAT2BRD4CYP3A4
SCHEMBL4116601 0.78 PTGER4 (0.43) PTGER4L3MBTL1BCAT2CYP3A4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187390-A1 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. 2005-08-25 US claimed
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 US disclosed
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 US disclosed
US-7511145-B2 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. (US) 2009-03-31 US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 US disclosed
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES GENELABS TECHNOLOGIES, INC. 2009-03-26 US disclosed
US-20050187390-A1 Bicyclic heteroaryl derivatives GENELABS TECHNOLOGIES, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081165-A1 BICYCLIC HETEROARYL DERIVATIVES HAVCR2, MAVS, ZC3HAV1 PTGER4 4135/4885L3MBTL1 1221/4885BCAT2 514/4885
US-20050187390-A1 Bicyclic heteroaryl derivatives HAVCR2, MAVS, ZC3HAV1 PTGER4 4135/4885L3MBTL1 1221/4885BCAT2 514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.